Michaela (on behalf of Balaji Prasad)'s questions to Tarsus Pharmaceuticals Inc (TARS) leadership • Q4 2024
Question
Michaela, on for Balaji Prasad, asked for clarification on the patient overlap between Ocular Rosacea and Demodex Blepharitis (DB), the perceived market opportunity for Ocular Rosacea, and the commercial differences between a gel formulation (TP-04) and an eye drop (XDEMVY).
Answer
Chief Operating Officer Seshadri Neervannan explained that while both conditions are caused by Demodex mites, Ocular Rosacea is a distinct disease with different clinical measures. He clarified that TP-04 is a specifically tailored gel for application to the eyelid and surrounding tissue, differing from the XDEMVY eye drop which targets eyelash follicles, making it a distinct product for a separate indication.